Loading viewer...
investor_presentation
Format: PDF investor_presentation
Immutep Limited presents its LAG-3 immunotherapy pipeline focused on oncology and autoimmune diseases as of September 2024. The presentation outlines multiple clinical-stage programs including eftilagimod alfa across various cancer indications and collaboration efforts with major pharmaceutical partners. The company is advancing therapies designed to unlock the immune system to fight cancer and autoimmune conditions.
conference
1 Pages
investor_presentation
23 Pages
Bank Albilad
Samsung Memory Investor Presentation 2019
investor_presentationinvestor_presentation
23 Pages
Samsung Electronics Co., Ltd.